Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
ProQR Therapeutics NV
PRQR
Healthcare
Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is...
transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:PRQR)
New Post
View:
Posts & Comments
Threaded Posts
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jun 18, 2024 6:45pm
ProQR Announces Presentation on its Axiomer(TM) RNA Editing
Just In: $PRQR ProQR Announces Presentation on its Axiomer(TM) RNA Editing Technology at RNA Editing SummitLEIDEN, Netherlands @ CAMBRIDGE, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics
...more
(291)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Apr 19, 2024 10:45am
ProQR Achieves Successful Defense of New Challenge to its Ax
News; $PRQR ProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP PortfolioLEIDEN, Netherlands @ CAMBRIDGE, Mass., April 19, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq
...more
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company
posted Dec 22, 2024 9:00am by
Voyageur Pharmaceuticals Ltd
-
|
Voyageur is securing supply chains in North America for barium, iodine and fullerene drug development and is aiming to gain efficiencies in production of contrast media products. The company anticipates this LOI will expand Voyageur’s project portfolio and diversify the Company’s product mix. The global contrast media market is valued at $6.3 billion with GE HealthCare projecting it will double over the next decade. ...read more
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 22, 2022 10:19am
PRQR ....In PB mode need to hold support at $2.57
and rally or ....it's done for the day
(69)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Dec 22, 2022 9:52am
PRQR ....early a.m runner
On watch
(0)
•••
Saaaa1
X
View Profile
View Bullboard History
Post by
Saaaa1
on May 06, 2021 8:55pm
$iMIN making moves in Ethereum Crypto !! 🚀🚀🚀🚀🚀
iMining Launches Fractional Staking to Enable Retail Investors to Participate in Ethereum 2.0's Proof-Of-Stake Mining Vancouver, British Columbia - (Newsfile Corp. - April 20, 2021) - iMining
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Introducing the NEW DealRoom: Your Gateway to Capital-Raising Investments